相似文献
1
L-Enantiomers of transition state analogue inhibitors bound to human purine nucleoside phosphorylase.
J Am Chem Soc. 2008 Jan 23;130(3):842-4. doi: 10.1021/ja710733g. Epub 2007 Dec 23.
2
Four generations of transition-state analogues for human purine nucleoside phosphorylase.
Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):4805-12. doi: 10.1073/pnas.0913439107. Epub 2010 Mar 8.
3
Transition state analogue discrimination by related purine nucleoside phosphorylases.
J Am Chem Soc. 2006 Jun 7;128(22):7126-7. doi: 10.1021/ja061403n.
4
Picomolar transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase and X-ray structure with MT-immucillin-A.
Biochemistry. 2004 Jan 13;43(1):9-18. doi: 10.1021/bi0358420.
5
Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase.
Biochemistry. 2002 Dec 10;41(49):14489-98. doi: 10.1021/bi026636f.
6
Over-the-barrier transition state analogues and crystal structure with Mycobacterium tuberculosis purine nucleoside phosphorylase.
Biochemistry. 2003 May 27;42(20):6057-66. doi: 10.1021/bi0343830.
7
Inhibition and structure of Toxoplasma gondii purine nucleoside phosphorylase.
Eukaryot Cell. 2014 May;13(5):572-9. doi: 10.1128/EC.00308-13. Epub 2014 Feb 28.
8
Syntheses and bio-activities of the L-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases.
Org Biomol Chem. 2006 Mar 21;4(6):1131-9. doi: 10.1039/b517883e. Epub 2006 Jan 26.
9
One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.
Biochemistry. 1998 Jun 16;37(24):8615-21. doi: 10.1021/bi980658d.
10
Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
J Med Chem. 2003 Jul 17;46(15):3412-23. doi: 10.1021/jm030145r.
引用本文的文献
1
Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation.
Sci Pharm. 2017 Jan 27;85(1):5. doi: 10.3390/scipharm85010005.
2
Tight binding enantiomers of pre-clinical drug candidates.
Bioorg Med Chem. 2015 Sep 1;23(17):5326-33. doi: 10.1016/j.bmc.2015.07.059. Epub 2015 Jul 30.
3
The ligand binding mechanism to purine nucleoside phosphorylase elucidated via molecular dynamics and machine learning.
Nat Commun. 2015 Jan 27;6:6155. doi: 10.1038/ncomms7155.
4
Catalytic site conformations in human PNP by 19F-NMR and crystallography.
Chem Biol. 2013 Feb 21;20(2):212-22. doi: 10.1016/j.chembiol.2013.01.009.
5
Ribocation transition state capture and rebound in human purine nucleoside phosphorylase.
Chem Biol. 2009 Sep 25;16(9):971-9. doi: 10.1016/j.chembiol.2009.07.012.
6
Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylase.
Biochemistry. 2009 Jun 16;48(23):5226-38. doi: 10.1021/bi9005896.
7
Loop-tryptophan human purine nucleoside phosphorylase reveals submillisecond protein dynamics.
Biochemistry. 2009 Apr 28;48(16):3658-68. doi: 10.1021/bi802339c.
8
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.
J Med Chem. 2009 Feb 26;52(4):1126-43. doi: 10.1021/jm801421q.
9
A beta-fluoroamine inhibitor of purine nucleoside phosphorylase.
J Med Chem. 2008 Sep 25;51(18):5880-4. doi: 10.1021/jm800792b.
本文引用的文献
1
Neighboring group participation in the transition state of human purine nucleoside phosphorylase.
Biochemistry. 2007 May 1;46(17):5038-49. doi: 10.1021/bi700147b. Epub 2007 Apr 4.
2
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Blood. 2006 Oct 1;108(7):2392-8. doi: 10.1182/blood-2006-03-007468. Epub 2006 Jun 15.
3
Syntheses and bio-activities of the L-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases.
Org Biomol Chem. 2006 Mar 21;4(6):1131-9. doi: 10.1039/b517883e. Epub 2006 Jan 26.
4
Insight into catalytically relevant correlated motions in human purine nucleoside phosphorylase.
J Phys Chem A. 2006 Jan 19;110(2):463-72. doi: 10.1021/jp051277u.
5
Energetic mapping of transition state analogue interactions with human and Plasmodium falciparum purine nucleoside phosphorylases.
J Biol Chem. 2005 Aug 26;280(34):30320-8. doi: 10.1074/jbc.M505033200. Epub 2005 Jun 16.
6
Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Curr Opin Drug Discov Devel. 2004 Mar;7(2):243-7.
7
Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases.
Biochemistry. 2004 Feb 17;43(6):1458-68. doi: 10.1021/bi0359123.
8
Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase.
J Biol Chem. 2003 Aug 22;278(34):31465-8. doi: 10.1074/jbc.C300259200. Epub 2003 Jul 3.
9
Ionic states of substrates and transition state analogues at the catalytic sites of N-ribosyltransferases.
Biochemistry. 2003 May 20;42(19):5694-705. doi: 10.1021/bi034003a.
10
Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase.
Biochemistry. 2002 Dec 10;41(49):14489-98. doi: 10.1021/bi026636f.
Zotero 插件